Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving viable micro-organism
Reexamination Certificate
2000-10-16
2002-12-24
Ketter, James (Department: 1636)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving viable micro-organism
C435S368000
Reexamination Certificate
active
06498018
ABSTRACT:
TECHNICAL FIELD OF THE INVENTION
This invention relates to isolation of human central nervous system stem cells, and methods and media for proliferating, differentiating and transplanting them.
BACKGROUND OF THE INVENTION
During development of the central nervous system (“CNS”), multipotent precursor cells, also known as neural stem cells, proliferate, giving rise to transiently dividing progenitor cells that eventually differentiate into the cell types that compose the adult brain. Stem cells (from other tissues) have classically been defined as having the ability to self-renew (i.e., form more stem cells), to proliferate, and to differentiate into multiple different phenotypic lineages. In the case of neural stem cells this includes neurons, astrocytes and oligodendrocytes. For example, Potten and Loeffler (Development, 110:1001, 1990) define stem cells as “undifferentiated cells capable of a) proliferation, b) self-maintenance, c) the production of a large number of differentiated functional progeny, d) regenerating the tissue after injury, and e) a flexibility in the use of these options.”
These neural stem cells have been isolated from several mammalian species, including mice, rats, pigs and humans. See, e.g., WO 93/01275, WO 94/09119, WO 94/10292, WO 94/16718 and Cattaneo et al.,
Mol. Brain Res.,
42, pp. 161-66 (1996), all herein incorporated by reference.
Human CNS neural stem cells, like their rodent homologues, when maintained in a mitogen-containing (typically epidermal growth factor or epidermal growth factor plus basic fibroblast growth factor), serum-free culture medium, grow in suspension culture to form aggregates of cells known as “neurospheres”. In the prior art, human neural stem cells have doubling rates of about 30 days. See, e.g., Cattaneo et al.,
Mol Brain Res.,
42, pp. 161-66 (1996). Upon removal of the mitogen(s) and provision of a substrate, the stem cells differentiate into neurons, astrocytes and oligodendrocytes. In the prior art, the majority of cells in the differentiated cell population have been identified as astrocytes, with very few neurons (<10%) being observed.
There remains a need to increase the rate of proliferation of neural stem cell cultures. There also remains a need to increase the number of neurons in the differentiated cell population. There further remains a need to improve the viability of neural stem cell grafts upon implantation into a host.
SUMMARY OF THE INVENTION
This invention provides novel human central nervous system stem cells, and methods and media for proliferating, differentiating and transplanting them. In one embodiment, this invention provides novel human stem cells with a doubling rate of between 5-10 days, as well as defined growth media for prolonged proliferation of human neural stem cells. In another embodiment, this invention provides a defined media for differentiation of human neural stem cells so as to enrich for neurons, oligodendrocytes, astrocytes, or a combination thereof. The invention also provides differentiated cell populations of human neural stem cells that provide previously unobtainable large numbers of neurons, as well as astrocytes and oligodendrocytes. This invention also provides novel methods for transplanting neural stem cells that improve the viability of the graft upon implantation in a host.
REFERENCES:
patent: 4753635 (1988-06-01), Sagen et al.
patent: 4980174 (1990-12-01), Sagen et al.
patent: 5082670 (1992-01-01), Gage
patent: 5175103 (1992-12-01), Lee et al.
patent: 5411883 (1995-05-01), Boss et al.
patent: 5580777 (1996-12-01), Bernard et al.
patent: 5612211 (1997-03-01), Wilson et al.
patent: 5639618 (1997-06-01), Gay
patent: 5672499 (1997-09-01), Anderson et al.
patent: 5688692 (1997-11-01), Jat
patent: 5750376 (1998-05-01), Weiss et al.
patent: 5753506 (1998-05-01), Johe
patent: 5766948 (1998-06-01), Gage et al.
patent: 5851832 (1998-12-01), Weiss et al.
patent: 5968829 (1999-10-01), Carpenter
patent: 5980885 (1999-11-01), Weiss et al.
patent: 6103530 (2000-08-01), Carpenter
patent: WO 89/03872 (1989-05-01), None
patent: WO 90/06757 (1990-06-01), None
patent: WO 91/02003 (1991-02-01), None
patent: WO 91/09936 (1991-07-01), None
patent: WO 91/17141 (1991-11-01), None
patent: WO 93/01275 (1993-01-01), None
patent: WO 93/09802 (1993-05-01), None
patent: WO 94/09119 (1994-04-01), None
patent: WO 97/10292 (1994-05-01), None
patent: WO 94/16718 (1994-08-01), None
patent: WO 95/00632 (1995-01-01), None
patent: WO 96/09543 (1996-03-01), None
patent: WO-9609543 (1996-03-01), None
patent: WO 96/15226 (1996-05-01), None
Anchan et al., “EGF and TGF-,&agr;. Stimulate Retinal Neuroepithelial Cell Proliferation in Vitro,”Neuron, 6(6):923-936 (1991).
Andres “Removal and reimplantation of the parietal cortex of mice during the first nine days of life: consequences for the barrelfield” Journal of Neural Transplantation 1(1): 11-12 (1989) (abstract).
Blakemore & Crang., “Extensive Oligodendrocyte Remyelination Following Injection of Cultured Central Nervous System,” Developmental Neuroscience, 10:1-11 (1988).
Bossart et al., “Epidermal growth factor stimulates colony formation and non-neuronal marker protein expression by human neuroblastoma in methylcellulose culture”, Anticancer Res 9:1496-1504, (1989).
Calof et al., “Regulation of Neurogenesis and neuronal differentiation in primary and immortalized cells from Mouse olfactory epithellum”, J. Cell Biol. 109(4 part 2): 57a, Abstract No. 307 (1989).
Calof et al., “Analysis of Neurogenesis in a Mammalian Neuroepithelium: Proliferation and Differentiation of an Olfactory Neuron Precursor in Vitro,”Neuron, 3:115-127 (1989).
Cattaneo and McKay, “Proliferation and differentiation of neuronal stem cells regulated by nerve growth factor,” Nature, 347:762-765 (1990).
Cattaneo et al., “Non-virally mediated gene transfer into human central nervous system precursor cells”, Mol. Brain Res., 42:161-66, (1996).
Cepko et al., “Immortalization of neural cells via retrovirus-mediated oncogene transduction,” Ann. Rev. Neurosci., 12:47-65 (1989).
Drago et al., “Fibroblast growth factor-mediated proliferation of central nervous system precursors depends on endogenous production of insulin-like growth factor I”, Proc. Natl. Acad. Sci. USA 88(6): 2199-21203, (1991).
Federoff et al. “Expression of nerve growth factor in vivo from a defective herpes simplex virus 1 vector prevents effects of axotomy on sympathetic ganglia” (Proc. Natl. Acad. Sci. USA 89(5): 1636-1640, 1992).
Franklin et al., “Transplanted type-1 astrocyystes facilities repair of demyelinating lesions by host oligodendrycytes in adult rat spinal cord”, Neuropathol Appl Neurobiol 17(3), 244, (1991).
Frederiksen et al., “Immortalization of precursor cells from the mammalian CNS,” Neuron, 1:439-448 (1998).
Frederiksen et al., “Proliferation and differentiation of rat neuroepithelial precursor cells in vivo,” The Journal of Neuroscience 8(4): 1144-1151 (1988).
Geller et al., “A Defective HSV-1 vector expressesEscherichia coli.62.-galactosidase in cultured peripheral neurons,” Science, 241:1667-1669 (1988).
Gensburger et al., “Brain basic fibroblast growth factor stimulates the proliferation of rat neuronal precursor cells in vitro,” FEBS Letts, 217(1):1-5 (1987).
Hall & Watt, “Stem cells: the generation and maintenance of cellular diversity,” Development, 106:619-633 (1989).
Hammang et al., “Myelination following transplantation of EGF-responsive neural stem cells into a myelin-deficient environment”, Experimental Neurology 147:84-95 (1997).
Hoffmann et al., “Transplantation of a polymer-encapsulated cell line genetically engineered to release NGF,” Exp. Neurol. 122:100-106 (1993).
Hunter et al., “Growth factor responses of enriched bipotential glial progenitors,” Developmental Brain Research, 54(2):235-248 (1990).
Isacson et al., “A primated model of Huntington's disease: cross-species implantation of striatal precursor cells to the excitotoxically lesioned baboon caudate-putamen”, Exp. Brain Res. 75(1): 213-220, (1989).
Jaenisch et al., “The cells of primitive neuroectodermal tumours may u
Cytotherapeutics, Inc.
Elrifi, Esq. Ivor R.
Karnakis, Esq. Christian V.
Ketter James
Mintz Levin Cohn Ferris Glovsky and Popeo P.C.
LandOfFree
Cultures of human CNS neural stem cells does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cultures of human CNS neural stem cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cultures of human CNS neural stem cells will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2934327